Johnson & Johnson reported strong first-quarter results with sales and earnings exceeding expectations, primarily driven by the successful OTC launch of ZYRTEC and effective cost restructuring. Despite some headwinds in the pharmaceutical and medical devices segments, the raised full-year guidance and robust pipeline initiatives suggest positive investor sentiment in the short term.

[1]